Business Model Breakdown
How Relay Therapeutics Inc Makes Money
RLAY
Market Cap
$2.6B
Annual Revenue
$8M
Profit Margin
0.0%
The Short Version
Relay Therapeutics is a biotechnology company focused on discovering and developing precision medicines, primarily in oncology, using its proprietary computational drug discovery platform called Dynamo. Instead of making money from selling approved drugs directly, it currently generates revenue through licensing its developed drug candidates to larger pharmaceutical companies, receiving upfront payments and potential future royalties upon drug approval and sales. Its long-term goal is to bring its own drugs to market, leveraging its platform to rapidly identify and advance novel therapies.
Where the Revenue Comes From
Licensing agreements (e.g., RLY-4008 to Elevar Therapeutics) (~100% of current revenue)
Future potential royalties on approved licensed drugs
Future potential direct sales of its own commercialized drugs
Who buys: Currently, pharmaceutical companies via licensing deals. Ultimately, patients and healthcare providers will be the end-users of their drugs.
Why It Works (Competitive Advantages)
- ✔Proprietary Dynamo computational drug discovery platform.
- ✔First-in-class pan-mutant selective PI3Kα inhibitor (zovegalisib) in Phase 3.
- ✔Differentiated precision oncology approach.
Economic Moat: Narrow (Intangible Assets/IP (proprietary Dynamo platform, drug patents), Cost Advantages (implied efficiency from computational discovery))
What Our Analysis Says
DVR Score as of April 9, 2026
Relay Therapeutics has demonstrated significant progress since the last analysis, achieving its first quarterly revenue in Q4 2025 from the out-licensed RLY-4008, and presenting positive Phase 1/2 data for its lead asset, zovegalisib (RLY-2608), now in Phase 3. The company's proprietary Dynamo platform and first-in-class assets position it strongly in the vast precision oncology market. Strong institutional buying, evidenced by Casdin Capital's recent ~$11.86M purchase, and analyst upgrades validate its potential. While substantial cash burn remains a risk requiring future financing, these milestones significantly de-risk the investment thesis, enhancing its 10x growth potential within 3-5 years if clinical success continues. The primary risk remains clinical trial outcomes.